Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Options Exercise Instructions
    • Top 40 Shareholders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

ASX Announcements 2012

  • 14 Dec 2012

    Biotron completes clinical stage of HIV clinical trial

  • 28 Nov 2012

    Results of Annual General Meeting

  • 28 Nov 2012

    Presentation to Annual General Meeting

  • 27 Nov 2012

    Commencement of three-month toxicology studies for BIT225

  • 9 Nov 2012

    Key Phase 2 HIV/HCV trial commenced

  • 26 Oct 2012

    Presentation to investors

  • 25 Oct 2012

    Annual Report for year ended 30 June 2012 and Notice of Annual General Meeting

  • 23 Oct 2012

    Quarterly Report 30 September 2012

  • 16 Oct 2012

    Biotron Limited to report new clinical data from BIT225 Hepatitis C Phase 2a trial in a late-breaking presentation at the AASLD 2012 annual conference

  • 11 Oct 2012

    October 2012 edition of BITNews

  • 12 Sep 2012

    Change of Director’s Interest Notice

  • 10 Sep 2012

    Change of Director’s Interest Notice

  • 31 Aug 2012

    Year End Accounts and Preliminary Final Report for year ended 30 June 2012

  • 27 Jul 2012

    Quarterly Report 30 June 2012

  • 8 May 2012

    May 2012 edition of BITNews

  • 20 Apr 2012

    Quarterly Report 31 March 2012

  • 3 Apr 2012

    Exercise of options

  • 7 Mar 2012

    Appointment of Directors

  • 28 Feb 2012

    Half-year report 31 December 2011

  • 15 Feb 2012

    CEO Presentation at International Investor Conference

  • 24 Jan 2012

    Quarterly Report 31 December 2011

  • 16 Jan 2012

    Response to ASX price query

  • 12 Jan 2012

    CEO presentation at Biotech Showcase San Francisco

  • 6 Jan 2012

    Exercise of options raises $8.0 million

  • <<
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • >>

Investor Centre

  • Investor Centre
    • ASX Announcements
    • Annual reports
    • Corporate Directory
    • Shareholder services
    • Top 40 Shareholders
    • Corporate Governance
    • Corporate Presentations
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 6 April 2021        Legal Notices and Privacy